Project: A first-in-class antibody therapy to combat Myocardial Ischemia-Reperfusion Injury
| Acronym | MYOAB (Reference Number: 114902) |
| Duration | 01/04/2021 - 01/10/2023 |
| Project Topic | MYOAB will deliver a first-in-class monoclonal antibody (mAb) therapy to combat myocardial ischemia-reperfusion injury (M-IRI) in Acute Coronary Syndrome (ACS) patients. Starting from two naturally occurring human antibodies, we adopt a screening and maturation cascade to identify an improved development candidate based on in-vitro and in-vivo efficacy, drug metabolism and pharmacokinetics (DMPK) and safety data. This mAb will be ready to enter IND enabling safety & toxicology studies. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 14 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Oxitope Pharma B.V. | Coordinator | Netherlands |
| 2 | Amsterdam University Medical Center | Partner | Netherlands |
| 3 | Hannover Medical School | Partner | Germany |
| 4 | Yumab GmbH | Partner | Germany |